Important News & Announcements

Stay up to date with the latest news and announcements from NASCSA.

Back to all news

LAPPA Publishes Report on Status of State Laws for Regulating Kratom

Posted 6/2/2024

The Legislative Analysis and Public Policy Association (LAPPA) has released an updated 50-state summaries report on kratom, an herbal substance that can produce opioid- and stimulant-like effects. The report, Kratom: Summary of State Laws, includes the statutory or regulatory citation(s) on the herb, requirements for product labels, penalties for violations, and more. Kratom and its two psychoactive ingredients, mitragynine and 7-hydroxymitragynine, are neither federally regulated nor considered controlled substances (CS). As of February 2024, however, 22 states and the District of Columbia have placed some types of restrictions on the herb or its components, such as classifying kratom?s ingredients as CS or regulating the possession, sale, and manufacturing process of kratom because of potential adverse effects. A copy of the summary can be found here.

Back to all news

Sponsor Spotlight

COMPASS Pathways

COMPASS Pathways is delighted to be a sponsor of NASCSA and looks forward to both engaging with controlled substances authorities, NASCSA leadership, and members to learn about their important work, and educate about our company's mission and the innovations underway using novel therapies.

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments.

We are developing innovative therapies and, when appropriate, combining them with psychological support and next-generation digital tools to forge new, sustainable mental health care pathways.

Our investigational COMP360 psilocybin therapy is currently undergoing phase 3 investigation in treatment-resistant depression. We are also assessing COMP360 in anorexia nervosa and post-traumatic stress disorder, across multiple clinical studies.

Learn more

All Sponsors